Panagiotis A. Konstantinopoulos

Panagiotis A. Konstantinopoulos

Top Cited Scholar 2025
Auto-generated profile, based on publicly available information

Panagiotis A. Konstantinopoulos

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2015 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
RCRaphael Ceccaldi
Raphael Ceccaldi
GSGeoffrey I. Shapiro
Geoffrey I. Shapiro
ADAlan D. D'ANdrea
Alan D. D'ANdrea
Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

1 December 2015 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
BHBrooke E. Howitt
Brooke E. Howitt
SSSachet A. Shukla
Sachet A. Shukla
LSLynette M. Sholl
Lynette M. Sholl
LRLauren L. Ritterhouse
Lauren L. Ritterhouse
JWJaclyn C. Watkins
Jaclyn C. Watkins
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
The Cancer Genome Atlas project identified 2 groups of endometrioid endometrial cancers (ECs) with high mutation frequency: an ultramutated group (7% of all tumors) that harbored mutations in the exonuclease domain of polymerase e (POLE), and a hypermutated group (28% of tumors) with microsatellite instability (MSI), the majority of which harbored MLH1 promoter methylation.1 The ultramutated POLE group exhibited an extremely high mutation rate (232 × 10−6 mutations/Mb) with a unique nucleotide change spectrum of increased C→A transversion frequency, whereas the hypermutated MSI group exhibited mutation rates of 18 × 10−6 mutations/Mb with variable length of DNA microsatellites due to an underlying deficiency in mismatch DNA repair.1-3 Mismatch DNA repair deficiency induces single-base mismatches that lead to point mutations in coding regions of genes, as well as insertions or deletions that lead to frame-shift mutations.

9 February 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
KSKyle C. Strickland
Kyle C. Strickland
BHBrooke E. Howitt
Brooke E. Howitt
SSSachet A. Shukla
Sachet A. Shukla
SRScott Rodig
Scott Rodig
LRLauren L. Ritterhouse
Lauren L. Ritterhouse
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer

1 December 2018 in Cell Reports
Verified
Journal Article
Open access
LDLiya Ding
Liya Ding
HKHye-Jung Kim
Hye-Jung Kim
Qiwei WangQiwei Wang
Qiwei Wang
MKMichael Kearns
Michael Kearns
TJTao Jiang
Tao Jiang
JZJean J. Zhao
Jean J. Zhao
PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune system remain unclear. We find that PARP inhibition by olaparib triggers robust local and systemic antitumor immunity involving both adaptive and innate immune responses through a STING-dependent antitumor immune response in mice bearing Brca1-deficient ovarian tumors. This effect is further augmented when olaparib is combined with PD-1 blockade. Our findings thus provide a molecular mechanism underlying antitumor activity by PARP inhibition and lay a foundation to improve therapeutic outcome for cancer patients.

1 August 2019 in JAMA Oncology
Verified
Journal Article
Closed access
PDF file
PKPanagiotis A. Konstantinopoulos
Panagiotis A. Konstantinopoulos
SWSteven Waggoner
Steven Waggoner
GVGregory A. Vidal
Gregory A. Vidal
MMMonica Mita
Monica Mita
JMJohn W. Moroney
John W. Moroney
PMPamela Munster
Pamela Munster
Ovarian cancer is the eighth leading cause of deaths due to cancer worldwide, with a 5-year survival rate ranging from 30% to 50%. Although most patients initially have platinum-sensitive ovarian carcinoma, their disease eventually becomes resistant or refractory to platinum-based chemotherapy.1,2 Some patients are unable to receive platinum-based chemotherapy owing to cumulative toxic effects or allergic reactions and receive non–platinum-based agents such as weekly paclitaxel, pegylated liposomal doxorubicin hydrochloride, or topotecan hydrochloride alone or in combination with bevacizumab.3,4 Owing to the risk of vascular toxic effects and gastrointestinal tract perforation, bevacizumab is contraindicated in approximately one-third of patients5; non–platinum-based monotherapy in these patients results in low response rates (10%-15%) and short durations of response (3-4 months).6

22 June 2020 in Nature Medicine
Verified
Journal Article
Open access
PDF file
BIBenjamin Izar
Benjamin Izar
ITItay Tirosh
Itay Tirosh
ESElizabeth H. Stover
Elizabeth H. Stover
IWIsaac Wakiro
Isaac Wakiro
MCMichael S. Cuoco
Michael S. Cuoco
ARAviv Regev
Aviv Regev
Malignant abdominal fluid (ascites) frequently develops in women with advanced high-grade serous ovarian cancer (HGSOC) and is associated with drug resistance and a poor prognosis1. To comprehensively characterize the HGSOC ascites ecosystem, we used single-cell RNA sequencing to profile ~11,000 cells from 22 ascites specimens from 11 patients with HGSOC. We found significant inter-patient variability in the composition and functional programs of ascites cells, including immunomodulatory fibroblast sub-populations and dichotomous macrophage populations. We found that the previously described immunoreactive and mesenchymal subtypes of HGSOC, which have prognostic implications, reflect the abundance of immune infiltrates and fibroblasts rather than distinct subsets of malignant cells2. Malignant cell variability was partly explained by heterogeneous copy number alteration patterns or expression of a stemness program. Malignant cells shared expression of inflammatory programs that were largely recapitulated in single-cell RNA sequencing of ~35,000 cells from additionally collected samples, including three ascites, two primary HGSOC tumors and three patient ascites-derived xenograft models. Inhibition of the JAK/STAT pathway, which was expressed in both malignant cells and cancer-associated fibroblasts, had potent anti-tumor activity in primary short-term cultures and patient-derived xenograft models. Our work contributes to resolving the HSGOC landscape3,4,5 and provides a resource for the development of novel therapeutic approaches.